{"pmid":32340759,"title":"Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19).","text":["Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19).","The novel coronavirus (SARS-CoV-2) infection which has been known as Coronavirus diseases 2019 (COVID-19) has become an endemic emergent situation by the World Health Organization. So far, no successful specific treatment has been found for this disease. As has been reported, most of non-survivor patients with COVID-19 (70%) had septic shock which was significantly higher than survived ones. Although the exact pathophysiology of septic shock in these patients is still unclear, it seems to be possible that part of it would be due to the administration of empiric antibiotics with inflammatory properties especially in the absence of bacterial infection. Herein, we have reviewed possible molecular pathways of septic shock in the patients who have received antibiotics with inflammatory properties which mainly is release of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF- alpha) through different routes. Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both empiric antibiotic therapy and reducing the inflammation to prevent septic shock in patients with diagnosed COVID-19.","Arch Med Res","Hantoushzadeh, Sedigheh","Norooznezhad, Amir Hossein","32340759"],"abstract":["The novel coronavirus (SARS-CoV-2) infection which has been known as Coronavirus diseases 2019 (COVID-19) has become an endemic emergent situation by the World Health Organization. So far, no successful specific treatment has been found for this disease. As has been reported, most of non-survivor patients with COVID-19 (70%) had septic shock which was significantly higher than survived ones. Although the exact pathophysiology of septic shock in these patients is still unclear, it seems to be possible that part of it would be due to the administration of empiric antibiotics with inflammatory properties especially in the absence of bacterial infection. Herein, we have reviewed possible molecular pathways of septic shock in the patients who have received antibiotics with inflammatory properties which mainly is release of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF- alpha) through different routes. Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both empiric antibiotic therapy and reducing the inflammation to prevent septic shock in patients with diagnosed COVID-19."],"journal":"Arch Med Res","authors":["Hantoushzadeh, Sedigheh","Norooznezhad, Amir Hossein"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340759","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.arcmed.2020.03.015","keywords":["antibiotics","coronavirus diseases 2019","inflammation","sars-cov-2","septic shock"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1665351883962712064,"score":8.574329,"similar":[{"pmid":32335068,"title":"Unexpected Blood Pressure Sensitivity to Angiotensin II in a COVID-19 Patient with ARDS and Septic Shock.","text":["Unexpected Blood Pressure Sensitivity to Angiotensin II in a COVID-19 Patient with ARDS and Septic Shock.","We report the case of an 88-year-old man with coronavirus disease 2019 (COVID-19) who presented with ARDS and septic shock. The patient had exquisite blood pressure sensitivity to low-dose angiotensin II (Ang-2), allowing for rapid liberation from high-dose vasopressors. We hypothesize that sensitivity to Ang-2 might be related to biologic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our case is suggestive of a potential role for synthetic Ang-2 for patients with COVID-19 and septic shock. Further studies are needed to confirm our observed clinical efficacy.","Chest","Wang, Hanyin","Das, Subhraleena","Wieruszewski, Patrick M","Taji, Jamil","Bartlett, Brian","Azad, Nabila","Chowdhury, Arnab","Kolar, Gururaj","Jain, Nitesh","Subla, Mir R","Khan, Syed Anjum","32335068"],"abstract":["We report the case of an 88-year-old man with coronavirus disease 2019 (COVID-19) who presented with ARDS and septic shock. The patient had exquisite blood pressure sensitivity to low-dose angiotensin II (Ang-2), allowing for rapid liberation from high-dose vasopressors. We hypothesize that sensitivity to Ang-2 might be related to biologic effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our case is suggestive of a potential role for synthetic Ang-2 for patients with COVID-19 and septic shock. Further studies are needed to confirm our observed clinical efficacy."],"journal":"Chest","authors":["Wang, Hanyin","Das, Subhraleena","Wieruszewski, Patrick M","Taji, Jamil","Bartlett, Brian","Azad, Nabila","Chowdhury, Arnab","Kolar, Gururaj","Jain, Nitesh","Subla, Mir R","Khan, Syed Anjum"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335068","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.015","keywords":["angiotensin ii","covid-19","sars-cov-2","septic shock"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1665172301949173761,"score":509.958},{"pmid":32171193,"title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","text":["Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.","J Biol Regul Homeost Agents","Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S","32171193"],"abstract":["Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy."],"journal":"J Biol Regul Homeost Agents","authors":["Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32171193","week":"202012|Mar 16 - Mar 22","doi":"10.23812/CONTI-E","keywords":["covid-19","il-1","il-6","pro-inflammatory cytokines","covi-19","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["swabs"],"e_drugs":["Adenosine"],"_version_":1664640874694311937,"score":380.09604},{"pmid":32324366,"title":"[Advanced organ support and life-sustaining therapies in critically ill COVID-19 infected patients].","text":["[Advanced organ support and life-sustaining therapies in critically ill COVID-19 infected patients].","In critically ill patients with COVID-19 infection, the cardiorespiratory system may collapse by the following mechanisms: (1) cytokine storm, haemophagocytosis - septic shock, (2) uncontrollable hypoxaemia, (3) specific organ failure or multiple organ failure. In this summary, we review the currently available therapeutic options for the treatment and prevention of the above conditions. Removal of cytokines by CytoSorb haemoperfusion has been used more and more frequently and with encouraging success in recent years to treat septic shock. In the case of hypoxaemia, which can no longer be treated with conventional mechanical ventilation, inhaled nitric oxide (iNO), inhaled epoprostenol and venovenous extracorporeal membrane oxygenation (VV-ECMO) are considered. A common component of mostly late-stage organ failure is acute renal failure, which requires the initiation of one of the available continuous renal replacement therapies. Orv Hetil. 2020; 161 (17): 704-709.","Orv Hetil","Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy","32324366"],"abstract":["In critically ill patients with COVID-19 infection, the cardiorespiratory system may collapse by the following mechanisms: (1) cytokine storm, haemophagocytosis - septic shock, (2) uncontrollable hypoxaemia, (3) specific organ failure or multiple organ failure. In this summary, we review the currently available therapeutic options for the treatment and prevention of the above conditions. Removal of cytokines by CytoSorb haemoperfusion has been used more and more frequently and with encouraging success in recent years to treat septic shock. In the case of hypoxaemia, which can no longer be treated with conventional mechanical ventilation, inhaled nitric oxide (iNO), inhaled epoprostenol and venovenous extracorporeal membrane oxygenation (VV-ECMO) are considered. A common component of mostly late-stage organ failure is acute renal failure, which requires the initiation of one of the available continuous renal replacement therapies. Orv Hetil. 2020; 161 (17): 704-709."],"journal":"Orv Hetil","authors":["Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324366","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31813","keywords":["covid-19","cytosorb","ecmo","inhalational nitric oxide","inhalalt nitrogen-oxid","intensive therapy","intenziv kezeles"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932837134336,"score":361.8512},{"pmid":32057209,"title":"[Pharmacotherapeutics for the New Coronavirus Pneumonia].","text":["[Pharmacotherapeutics for the New Coronavirus Pneumonia].","The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.","Zhonghua Jie He He Hu Xi Za Zhi","Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H","32057209"],"abstract":["The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32057209","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0012","keywords":["antibiotics","glucocorticosteroid","new coronavirus pneumonia","pharmacotherapeutics"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China","Interferon-alpha"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Ribavirin"],"_version_":1664640875289903104,"score":351.51373},{"pmid":32253400,"title":"Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways.","text":["Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways.","Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease with few successful treatments, and is strongly associated with cigarette smoking (CS). Since the novel coronavirus has spread worldwide seriously, there is growing concern that patients who have chronic respiratory conditions like COPD can easily be infected and are more prone to having severe illness and even mortality because of lung dysfunction. Loquat leaves have long been used as an important material for both pharmaceutical and functional applications in the treatment of lung disease in Asia, especially in China and Japan. Total flavonoids (TF), the main active components derived from loquat leaves, showed remarkable anti-inflammatory and antioxidant activities. However, their protective activity against CS-induced COPD airway inflammation and oxidative stress and its underlying mechanism still remain not well-understood. The present study uses a CS-induced mouse model to estimate the morphological changes in lung tissue. The results demonstrated that TF suppressed the histological changes in the lungs of CS-challenged mice, as evidenced by reduced generation of pro-inflammatory cytokines including interleukin 6 (IL-6), IL-1beta, tumor necrosis factor alpha (TNF-alpha), nitric oxide (NO), and inducible nitric oxide synthase (iNOS) and diminished the protein expression of transient receptor potential vanilloid 1 (TRPV1). Moreover, TF also inhibited phosphorylation of IKK, IkappaB and NFkappaB and increased p-Akt. Interestingly, TF could inhibit CS-induced oxidative stress in the lungs of COPD mice. TF treatment significantly inhibited the level of malondialdehyde (MDA) and increased the activity of superoxide dismutase (SOD). In addition, TF markedly downregulated TRPV1 and cytochrome P450 2E1 (CYP2E1) and upregulated the expression of SOD-2, while the p-JNK level was observed to be inhibited in COPD mice. Taken together, our findings showed that the protective effect and putative mechanism of the action of TF resulted in the inhibition of inflammation and oxidative stress through the regulation of TRPV1 and the related signal pathway in lung tissues. It suggested that TF derived from loquat leaves could be considered to be an alternative or a new functional material and used for the treatment of CS-induced COPD.","Food Funct","Jian, Tunyu","Chen, Jian","Ding, Xiaoqin","Lv, Han","Li, Jiawei","Wu, Yuexian","Ren, Bingru","Tong, Bei","Zuo, Yuanyuan","Su, Kelei","Li, Weilin","32253400"],"abstract":["Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease with few successful treatments, and is strongly associated with cigarette smoking (CS). Since the novel coronavirus has spread worldwide seriously, there is growing concern that patients who have chronic respiratory conditions like COPD can easily be infected and are more prone to having severe illness and even mortality because of lung dysfunction. Loquat leaves have long been used as an important material for both pharmaceutical and functional applications in the treatment of lung disease in Asia, especially in China and Japan. Total flavonoids (TF), the main active components derived from loquat leaves, showed remarkable anti-inflammatory and antioxidant activities. However, their protective activity against CS-induced COPD airway inflammation and oxidative stress and its underlying mechanism still remain not well-understood. The present study uses a CS-induced mouse model to estimate the morphological changes in lung tissue. The results demonstrated that TF suppressed the histological changes in the lungs of CS-challenged mice, as evidenced by reduced generation of pro-inflammatory cytokines including interleukin 6 (IL-6), IL-1beta, tumor necrosis factor alpha (TNF-alpha), nitric oxide (NO), and inducible nitric oxide synthase (iNOS) and diminished the protein expression of transient receptor potential vanilloid 1 (TRPV1). Moreover, TF also inhibited phosphorylation of IKK, IkappaB and NFkappaB and increased p-Akt. Interestingly, TF could inhibit CS-induced oxidative stress in the lungs of COPD mice. TF treatment significantly inhibited the level of malondialdehyde (MDA) and increased the activity of superoxide dismutase (SOD). In addition, TF markedly downregulated TRPV1 and cytochrome P450 2E1 (CYP2E1) and upregulated the expression of SOD-2, while the p-JNK level was observed to be inhibited in COPD mice. Taken together, our findings showed that the protective effect and putative mechanism of the action of TF resulted in the inhibition of inflammation and oxidative stress through the regulation of TRPV1 and the related signal pathway in lung tissues. It suggested that TF derived from loquat leaves could be considered to be an alternative or a new functional material and used for the treatment of CS-induced COPD."],"journal":"Food Funct","authors":["Jian, Tunyu","Chen, Jian","Ding, Xiaoqin","Lv, Han","Li, Jiawei","Wu, Yuexian","Ren, Bingru","Tong, Bei","Zuo, Yuanyuan","Su, Kelei","Li, Weilin"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253400","week":"202015|Apr 06 - Apr 12","doi":"10.1039/c9fo02921d","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China","Japan","IkappaB","NFkappaB","Eriobotrya"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["Flavonoids","Superoxides","Nitric Oxide","Malondialdehyde"],"_version_":1664640769881800704,"score":339.4095}]}